Health BMS Pays $100M for Next-Gen Orum Therapeutics ADC for Blood Cancers January 17, 2024 145 TelecomApril 3, 2026Democrat rips Polymarket for taking bets on fate of US pilot shot down over Iran TelecomApril 3, 2026A third of Americans planning to invest in high-risk, speculative assets: Study TelecomApril 3, 2026Anthropic launches new corporate PAC to ramp up election spending TelecomApril 3, 2026FBI labels data breach ‘major incident,’ notifies Congress TelecomApril 3, 2026Palantir-linked campaign donations put Democrats in tight spot Bristol Myers Squibb is expanding its scope in cancer by acquiring rights to a Phase 1-ready Orum Therapeutics program that brings a new twist to antibody drug conjugates. The deal is the latest business development move in the hot field of ADCs. Prime Plus Facebook Twitter Pinterest WhatsApp SportsApril 4, 2026Celtics’ Jaylen Brown Drops Honest Take on Left Hand Jokes Sports Red Sox’s Marcelo Mayer Sends Strong Message in Home Opener April 4, 2026 Sports Valero Texas Open Cut Sees Big Names Miss the Weekend April 4, 2026 Sports Lakers Hit With More Bad News on Luka Doncic Hamstring Injury April 4, 2026
